Global Glioblastoma Multiforme (GBM) Drugs Market Expected to Reach Nearly $1.4 Billion by 2025

Strategic Insights -

The global GBM drugs market is expected to reach nearly $1.4 billion by 2025, expanding at a compound annual growth rate (CAGR) of 12.6% during the forecast period. This growth is driven by the rising geriatric population, growing incidence cases, and a rich clinical pipeline of new products. Despite technological advances in surgery and radio-chemotherapy, GBM remains largely resistant to treatment, and the standard treatment for GBM is still surgery. The American Association of Neurological Surgeons reports that over 241,000 people die each year from brain or nervous system cancer, with GBM being the most common form of the disease.

Key Takeaways:

  • The global GBM drugs market is expected to reach nearly $1.4 billion by 2025, growing at a CAGR of 12.6% during the forecast period.
  • The growth is driven by the rising geriatric population, growing incidence cases, and a rich clinical pipeline of new products.
  • Despite technological advances, GBM remains largely resistant to treatment, and surgery is still the standard treatment.
  • The American Association of Neurological Surgeons reports that over 241,000 people die each year from brain or nervous system cancer, with GBM being the most common form of the disease.
  • Active biotech companies with recent developments include Nascent Biotech, Inc. (OTCQB: NBIO), Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Merck & Co., Inc. (NYSE: MRK), and Clovis Oncology, Inc. (NASDAQ: CLVS).
  • Nascent Biotech, Inc. (OTCQB: NBIO) is planning to begin phase 1 human trials for a treatment of brain cancer, including GBM, using its monoclonal antibody, Pritumumab.
  • Bristol-Myers Squibb Company (NYSE: BMY) has announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Applications (MAA) for idecabtagene vicleucel (ide-cel) and CC-486.
  • AstraZeneca PLC (NYSE: AZN) has announced that LYNPARZA has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
  • Merck & Co., Inc. (NYSE: MRK) has announced a collaboration agreement with Ridgeback Biotherapeutics LP to develop EIDD-2801, an orally available antiviral candidate for the treatment of patients with COVID-19.
  • Clovis Oncology, Inc. (NASDAQ: CLVS) has announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer (mCRPC).

Statistics:

  • The global GBM drugs market is expected to reach nearly $1.4 billion by 2025.
  • The market will grow at a CAGR of 12.6% during the forecast period.
  • Over 241,000 people die each year from brain or nervous system cancer, with GBM being the most common form of the disease.
  • The patient population with HRR gene mutations associated with mCRPC is approximately 20-30%.
  • Merck & Co., Inc. (NYSE: MRK) has invested in the development of EIDD-2801, an orally available antiviral candidate.

Sources:

  • Financialnewsmedia.com
  • PRNewswire
  • Grand View Research
  • American Association of Neurological Surgeons
  • Nascent Biotech, Inc. (OTCQB: NBIO)
  • Bristol-Myers Squibb Company (NYSE: BMY)
  • AstraZeneca PLC (NYSE: AZN)
  • Merck & Co., Inc. (NYSE: MRK)
  • Clovis Oncology, Inc. (NASDAQ: CLVS)
  • European Medicines Agency (EMA)
  • U.S. Food and Drug Administration (FDA)
  • New England Journal of Medicine
  • Financialnewsmedia.com disclosure: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.